The Bull Case For Teva (TEVA) Could Change Following UZEDY's FDA Approval for Bipolar I Disorder Expansion

• Teva Pharmaceuticals and Medincell recently announced that the U.S. FDA approved UZEDY (risperidone) as a once-monthly extended-release injectable for the maintenance treatment of bipolar I disorder in adults, expanding its indications beyond schizophrenia.
• This approval introduces the first subcutaneous, long-acting risperidone formulation using proprietary SteadyTeq technology, potentially enhancing treatment adherence for a condition affecting over 3.40 million adults in the U.S.
• We'll examine how UZEDY's expanded FDA approval for bipolar I disorder could impact Teva's branded product growth narrative.

These 10 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Teva Pharmaceutical Industries Investment Narrative Recap

To own Teva Pharmaceutical Industries stock today, you need to believe the company's pivot toward branded medications and innovative products like UZEDY can offset flat generics performance and help deliver sustained earnings growth, despite a heavy debt load. The FDA's latest approval for UZEDY in bipolar I disorder supports Teva’s short-term growth catalyst, expanded branded drug sales, but the risk of upcoming net price reductions due to the Inflation Reduction Act remains material, especially for key drugs like AUSTEDO.

Among the company’s recent announcements, the September regulatory approval for UZEDY in South Korea stands out, highlighting the momentum behind this product following its 2023 U.S. launch and its contribution to branded revenue growth, critical as Teva continues to diversify away from legacy generics and enhance its financial profile.

Yet despite ongoing product launches, investors should pay close attention to the potential for pressure on branded drug margins from upcoming U.S. price negotiations...

Read the full narrative on Teva Pharmaceutical Industries (it's free!)

Teva Pharmaceutical Industries' outlook projects $17.8 billion in revenue and $1.5 billion in earnings by 2028. This is based on an expected annual revenue growth rate of 2.3% and an earnings increase of $1.657 billion from current earnings of -$157 million.

Uncover how Teva Pharmaceutical Industries' forecasts yield a $24.22 fair value, a 20% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members have published 14 fair value estimates for Teva ranging from US$24.22 to US$58.33 per share. With branded product momentum building but the risk of price reform looming, individual assessments of the company’s future growth and value can vary widely, explore the breadth of these perspectives for deeper insight.

Explore 14 other fair value estimates on Teva Pharmaceutical Industries - why the stock might be worth over 2x more than the current price!

Build Your Own Teva Pharmaceutical Industries Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Teva Pharmaceutical Industries research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free Teva Pharmaceutical Industries research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Teva Pharmaceutical Industries' overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The end of cancer? These 28 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com